Hashimoto’s vs Hypothyroidism: What’s the Difference

Hypothyroidism is a hormone deficiency, while Hashimoto's thyroiditis is an autoimmune disease and the most common reason that deficiency develops. In iodine-sufficient countries such as the United States, Hashimoto's accounts for roughly 90% of hypothyroidism, and a thyroid peroxidase (TPO) antibody test is what tells the two apart [2].

The Core Distinction

Hypothyroidism means your thyroid gland does not produce enough thyroid hormone. It's a description of a state. It tells you what is happening but not why.

Hashimoto's thyroiditis is an autoimmune disease where your immune system produces antibodies that attack and gradually destroy thyroid tissue. It tells you why the thyroid is failing [1]. The disease goes by several names: Hashimoto's disease, chronic lymphocytic thyroiditis and autoimmune thyroiditis all describe the same process, and clinicians often shorten it to HT.

Think of it this way: if hypothyroidism is a flat tire, Hashimoto's is the nail in the road. Fixing the flat (levothyroxine) gets you driving again, but removing the nail (addressing the autoimmune process) prevents future flats.

Most doctors treat both conditions identically: prescribe levothyroxine, check TSH every 6-12 months, adjust dose as needed. This approach manages the hormone deficiency effectively. But it ignores the ongoing autoimmune destruction in Hashimoto's patients, which may have implications for long-term outcomes and associated conditions.

Is Hashimoto's the same as hypothyroidism?

Hashimoto's is not the same as hypothyroidism. Hashimoto's is one cause of hypothyroidism, and hypothyroidism is one possible result of Hashimoto's. A person can have Hashimoto's antibodies with normal hormone levels, and a person can have hypothyroidism after thyroid surgery with no autoimmunity at all.

Both are common. According to Hollowell and colleagues (2002), hypothyroidism was present in 4.6% of the US population in NHANES III (0.3% overt and 4.3% subclinical), and TPO antibodies were positive in 11.3% of people who did not report thyroid disease [2].

What Causes Each Condition

Causes of Hypothyroidism

Hypothyroidism has multiple causes:

• Hashimoto's thyroiditis: The most common cause (approximately 90% of cases in the US and Europe) [2]
• Thyroid surgery: Partial or total thyroidectomy for cancer, nodules, or Graves' disease
• Radioactive iodine therapy: Used to treat hyperthyroidism, often results in permanent hypothyroidism
• External radiation: Head and neck radiation for cancer treatment
• Medications: Lithium, amiodarone, immune checkpoint inhibitors, tyrosine kinase inhibitors
• Iodine deficiency: The leading cause worldwide, though uncommon in the US due to iodized salt
• Pituitary disorders: Central hypothyroidism from pituitary tumors or damage (rare)
• Congenital hypothyroidism: Absent or underdeveloped thyroid gland at birth

Causes of Hashimoto's

Hashimoto's has a complex etiology involving genetic susceptibility, environmental triggers, and immune dysregulation:

• Genetics: HLA-DR3, HLA-DR4, HLA-DR5, and CTLA-4 gene variants increase susceptibility. First-degree relatives have a 20-fold increased risk [3].
• Environmental triggers: Excess iodine intake, selenium deficiency, vitamin D deficiency, viral infections (hepatitis C, Epstein-Barr virus), cigarette smoking, and stress
• Hormonal factors: 5-10 times more common in women than men, with peaks during puberty, pregnancy, and menopause. Estrogen modulates immune function in ways that predispose to autoimmunity.
• Gut permeability: Increased intestinal permeability allows larger molecules into the bloodstream, potentially triggering immune responses through molecular mimicry. This is a working hypothesis with limited direct evidence in people with Hashimoto's.

Symptoms: Do Hashimoto's and Hypothyroidism Feel Different?

Hashimoto's and hypothyroidism from other causes produce the same core symptoms once hormone levels fall, because the symptoms come from the hormone shortage itself. Fatigue, feeling cold, constipation, dry skin, thinning hair, weight gain, low mood, slowed thinking and heavier menstrual periods are typical of both, according to the Lancet review of hypothyroidism by Chaker, Bianco, Jonklaas and Peeters (2017) [11].

Hashimoto's adds a few features of its own. Some people notice fullness at the front of the neck from an enlarged, firm thyroid (a goiter). Others have brief spells of palpitations, anxiety or heat intolerance when inflamed tissue leaks stored hormone, an episode called hashitoxicosis, before levels settle lower again.

Symptoms alone cannot tell you which condition you have. How the autoimmune disease develops is covered in our overview of Hashimoto's thyroiditis, and the wider range of complaints linked to an underactive or overactive gland is in common thyroid symptoms.

How They Progress Differently

Hypothyroidism (Non-Hashimoto's)

When hypothyroidism results from surgery, radiation, or medication, the cause is clear and the timeline is predictable. Thyroid function drops, hormone replacement begins, and with proper dosing, most patients feel well. The underlying cause is static: you're not losing more thyroid tissue over time (unless the original condition recurs).

Levothyroxine doses tend to be stable once optimized. Monitoring is routine.

Hashimoto's Thyroiditis

Hashimoto's follows a different trajectory with distinct phases [4]:

Phase 1: Euthyroid Hashimoto's. Antibodies are elevated, but TSH and thyroid hormones remain normal. This phase can last years. Most patients are undiagnosed unless antibodies are tested incidentally. Some patients experience symptoms even in this phase, possibly due to local thyroid inflammation affecting hormone pulsatility.

Phase 2: Subclinical hypothyroidism. TSH rises above normal (typically 4.5-10 mIU/L), but free T4 remains within range. The remaining thyroid tissue is working harder to compensate. Symptoms may or may not be present. Treatment at this stage is debated, but most endocrinologists treat if TSH exceeds 10 or if the patient is symptomatic, pregnant, or trying to conceive.

Phase 3: Overt hypothyroidism. TSH is elevated, free T4 is low. Symptoms are usually present. Treatment with levothyroxine is standard.

Ongoing: Even on adequate levothyroxine, the autoimmune process continues. Levothyroxine doses often need gradual increases over years as more thyroid tissue is destroyed. Some patients eventually require higher doses than would be expected from their body weight alone.

The combination of a raised TSH and positive antibodies carries the highest risk of progression. In the 20-year follow-up of the Whickham Survey in northern England, Vanderpump and colleagues (1995) found that women with both findings at the first survey had 38 times the odds of developing hypothyroidism, compared with odds of about 8 for either finding alone [12].

How Is Hashimoto's Diagnosed Compared With Hypothyroidism?

Hypothyroidism is diagnosed with two blood tests, TSH and free T4, while Hashimoto's is diagnosed by adding a TPO antibody test and sometimes a thyroid ultrasound. A high TSH shows the pituitary is pushing a struggling gland. Positive TPO antibodies show that the reason is autoimmune.

Many people are diagnosed with hypothyroidism on TSH alone and never have antibodies checked. Because treatment of the hormone deficiency is the same, the antibody result does not change the levothyroxine prescription, but it does change monitoring, family screening and attention to related autoimmune conditions.

Key Differences at a Glance

Why the Distinction Matters for Treatment

Levothyroxine Isn't the Whole Story

For non-autoimmune hypothyroidism, levothyroxine is usually all that is needed. You replace the missing hormone, symptoms resolve, and that's the end of the story for most patients.

Levothyroxine is synthetic T4, approved by the FDA and recommended as the standard treatment for hypothyroidism of any cause in the American Thyroid Association guidelines led by Jonklaas (2014) [13]. Those guidelines put full replacement for a person with no working thyroid at about 1.6 mcg per kg of body weight per day, with lower starting doses for older adults and people with heart disease. It is best absorbed on an empty stomach and kept apart from calcium and iron supplements.

For Hashimoto's, levothyroxine replaces thyroid hormone but does nothing to slow the autoimmune attack. This matters because:

• Doses escalate over time: As more thyroid tissue is destroyed, you need progressively more replacement hormone
• Residual symptoms persist: Some Hashimoto's patients report persistent fatigue, brain fog, and weight issues despite “normal” labs. One hypothesis is that the inflammatory cytokines from the autoimmune process contribute to symptoms independent of thyroid hormone levels [5]. Our piece on feeling unwell when blood work comes back normal looks at this gap in more detail.
• Autoimmune clustering: Having one autoimmune disease increases the risk of developing others. Hashimoto's patients have elevated rates of celiac disease, type 1 diabetes, pernicious anemia, vitiligo, and Addison's disease.

Immune Modulation Strategies

While no FDA-approved immunotherapy exists specifically for Hashimoto's, several strategies have been studied for lowering antibody levels. The evidence ranges from meta-analyses of randomized trials to small observational studies:

• Selenium supplementation (200 mcg/day): Reduces TPO antibodies by 20-40% in multiple RCTs, and the meta-analysis by Toulis and colleagues (2010) found a significant fall in antibody titers after three months [6]. Lower antibodies have not been shown to change long-term thyroid function.
• Gluten elimination: Lowers antibodies in a subset of patients, particularly those with elevated tissue transglutaminase or subclinical gluten sensitivity. The supporting studies are small.
• Vitamin D optimization: Maintaining levels above 40 ng/mL correlates with lower antibody titers in observational studies, which cannot show cause and effect.
• Stress management: Chronic psychological stress elevates cortisol and is thought to shift the Th1/Th2 balance in ways that worsen autoimmune activity
• Gut barrier support: Addressing intestinal permeability may reduce the antigenic load driving the autoimmune response

None of these replace levothyroxine. They complement it by targeting the autoimmune process that levothyroxine ignores.

Some integrative and functional medicine clinicians also prescribe low dose naltrexone (LDN) off label for Hashimoto's. Human data are limited to small studies and case reports, so it remains experimental; our review of LDN for Hashimoto's covers what has and has not been studied.

T4/T3 Combination Therapy: The Ongoing Debate

Standard treatment uses levothyroxine (T4) alone. Your body converts T4 to the active hormone T3 in peripheral tissues. For most patients, this works well.

A subset of Hashimoto's patients report persistent symptoms on T4 monotherapy despite normal TSH. Some research suggests that Hashimoto's-related destruction includes the type 2 deiodinase pathway, impairing T4-to-T3 conversion. The DIO2 gene polymorphism (Thr92Ala), present in roughly 16% of the population, may further compromise conversion [7].

Combination T4/T3 therapy (levothyroxine plus liothyronine) or desiccated thyroid extract (which contains both T4 and T3) is preferred by some patients and prescribed by some clinicians. The evidence is mixed: some RCTs show patient preference for combination therapy without objective improvements in cognitive or metabolic outcomes, while others show measurable benefit in specific subgroups [8].

The 2012 European Thyroid Association guidelines by Wiersinga and colleagues allow a trial of combination therapy for patients who remain unwell on adequate T4, as an experimental approach [8]. The 2014 American Thyroid Association guidelines found insufficient evidence to recommend it routinely [13]. Liothyronine is FDA approved; desiccated thyroid extract, made from pig thyroid, is prescription only but has not been through FDA new drug approval.

This debate is more relevant for Hashimoto's patients than for non-autoimmune hypothyroidism, because the autoimmune destruction may preferentially affect conversion capacity.

Treatment options compared

Monitoring Differences

For non-autoimmune hypothyroidism, monitoring is straightforward: check TSH and free T4 annually, adjust levothyroxine if needed. After a dose change, the ATA guidelines (2014) recheck TSH after about 6 to 8 weeks, because that is how long levels take to settle [13].

For Hashimoto's, a more thorough monitoring approach is warranted:

• TSH and free T4/T3: Every 6-12 months (more frequently if symptomatic or adjusting dose)
• TPO and Tg antibodies: Annually, to track autoimmune activity. Declining antibodies suggest the immune process is quieting; rising antibodies may predict increased thyroid destruction. Many endocrinologists do not repeat antibody tests once the diagnosis is made, so this is a point to discuss with your own clinician.
• Vitamin D, selenium, iron, ferritin, B12: Annually. Deficiencies are common and worsen both thyroid function and symptoms.
• Screening for associated conditions: Celiac disease panel (especially if GI symptoms are present), fasting glucose/HbA1c, CBC with differential
• Thyroid ultrasound: If nodules are detected or the gland is enlarging, periodic imaging helps distinguish benign Hashimoto's changes from concerning nodules requiring biopsy [9]

Can You Have Hashimoto's Without Hypothyroidism?

Yes. This is euthyroid Hashimoto's, and it's more common than most people realize. Some estimates suggest that up to 10-12% of the general population has elevated thyroid antibodies without overt thyroid dysfunction [10].

Whether euthyroid Hashimoto's should be treated is debated. Some patients are clearly symptomatic with normal labs, suggesting that the autoimmune inflammation itself produces symptoms. Others remain completely asymptomatic for life.

At minimum, euthyroid Hashimoto's warrants monitoring. Roughly 5% of these patients progress to overt hypothyroidism per year, meaning most will eventually need treatment. Pregnancy deserves extra attention, because TPO antibody positive women are more likely to develop hypothyroidism during and after pregnancy.

Can You Have Hypothyroidism Without Hashimoto's?

Yes, in roughly 10% of hypothyroidism cases in iodine-sufficient countries. Post-surgical, post-radiation, medication-induced, and congenital hypothyroidism all occur without autoimmune involvement. Thyroid antibodies are negative, and treatment focuses purely on hormone replacement without the additional autoimmune considerations.

Temporary hypothyroidism is a third pattern. Postpartum thyroiditis and painless (silent) thyroiditis can cause a few months of low thyroid hormone that resolves on its own, as Pearce, Farwell and Braverman describe in their NEJM review (2003) [4]. Some of these cases are early autoimmune disease and later become permanent.

Who Treats Hashimoto's and Hypothyroidism?

Primary care physicians diagnose and manage most hypothyroidism, and endocrinologists take over when the diagnosis is unclear, doses are hard to stabilize, nodules appear, or a patient is pregnant. Integrative, functional medicine and naturopathic clinicians often see Hashimoto's patients who want attention to the autoimmune side as well as the hormone, usually alongside their regular doctor rather than instead of one.

Clinics that offer hormone replacement therapy frequently include thyroid testing and thyroid medication in their care, though services differ from clinic to clinic, so confirm thyroid care before booking. Our guide to hormone therapy, its uses and evidence explains how these practices typically work, and most of this care is cash pay outside insurance networks.

Regenerated.com is free for patients, and listing order in the directory is not a paid ranking. Featured slots are clearly labeled and capped, and Verified means the clinic has completed the credential checks described in how Featured, Verified and organic listings differ. Being listed is not an endorsement, so ask any clinic how it manages thyroid medication and who reviews your labs.

The Practical Takeaway

If you've been told you have hypothyroidism, ask whether thyroid antibodies were checked. If not, request them. Knowing whether your hypothyroidism is autoimmune changes your monitoring plan, dietary considerations, and the conversation about persistent symptoms that standard treatment might not fully address.

If you've been told you have Hashimoto's, understand that you're managing two things: a hormone deficiency and an autoimmune disease. Levothyroxine handles the first. The second requires attention to diet, nutrients, gut health, stress, and vigilance for other autoimmune conditions. Women going through menopause should know that thyroid symptoms and menopausal symptoms overlap heavily, which makes a clear antibody and TSH result especially useful.

Related Reading

• Hashimoto’s Thyroiditis: The Evidence-Based Guide (Pillar)
• Hashimoto’s Diet: What to Eat and What to Avoid
• Hashimoto’s Symptoms: Early Signs Most People Miss
• Bioidentical Hormone Therapy (BHRT): Benefits, Risks, and Who It’s For
• What a Hashimoto's flare feels like and what drives it

Frequently Asked Questions

What is the difference between Hashimoto's and hypothyroidism?

Hypothyroidism is a hormonal state in which the thyroid makes too little hormone, while Hashimoto's is an autoimmune disease in which antibodies attack and gradually destroy thyroid tissue. Hashimoto's is the most common cause of hypothyroidism, accounting for roughly 90% of cases in the US and Europe. Put simply, if hypothyroidism is a flat tire, Hashimoto's is the nail in the road. A TPO antibody test shows which one you are dealing with.

Can you have Hashimoto's without having hypothyroidism?

Yes. In euthyroid Hashimoto's, thyroid antibodies are elevated while TSH and thyroid hormones remain normal, and it is estimated to affect 10 to 12% of the general population. Roughly 5% of these people progress to overt hypothyroidism each year. The disease typically moves through three phases: euthyroid, subclinical hypothyroidism with a raised TSH, and overt hypothyroidism with low free T4. Regular TSH checks catch the change when it happens.

How is Hashimoto's diagnosed?

Hashimoto's is diagnosed with a TPO antibody blood test, which is positive in 90 to 95% of cases, together with TSH and free T4 to stage thyroid function. Subclinical hypothyroidism shows a TSH of typically 4.5 to 10 mIU/L with free T4 in range, while overt hypothyroidism shows a raised TSH and low free T4. A thyroid ultrasound showing a heterogeneous, hypoechoic pattern with pseudonodules supports the diagnosis, especially when antibodies are negative.

What is the standard treatment, and does it stop the autoimmune attack?

Levothyroxine, a synthetic T4, is the standard treatment for both Hashimoto's and other forms of hypothyroidism. It replaces the missing hormone but does not slow the autoimmune attack in Hashimoto's, so thyroid tissue loss continues and doses often rise over the years. Combination T4/T3 therapy with liothyronine is an option some clinicians try for persistent symptoms, but trial results are mixed and the American Thyroid Association does not recommend it routinely.

Do any diet or supplement strategies help lower thyroid antibodies?

Selenium at 200 mcg per day has the strongest evidence, lowering TPO antibodies by 20 to 40% in randomized trials summarized in a 2010 meta-analysis. Gluten elimination lowers antibodies in a subset of patients, and vitamin D levels above 40 ng/mL correlate with lower antibody titers in observational studies. Stress management and gut barrier support are also used. None of these replace levothyroxine, and lower antibodies have not been shown to preserve thyroid function long term.

Who is most at risk for Hashimoto's?

Women are at highest risk: Hashimoto's is 5 to 10 times more common in women than men, with peaks around puberty, pregnancy and menopause. First-degree relatives of someone with Hashimoto's have a 20-fold increased risk, and gene variants such as HLA-DR3, HLA-DR4, HLA-DR5 and CTLA-4 raise susceptibility. Environmental triggers include excess iodine, low selenium, low vitamin D, viral infections such as hepatitis C and Epstein-Barr virus, smoking and stress.

Sources

1. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391-397. doi:10.1016/j.autrev.2014.01.007 ↩
2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): NHANES III. J Clin Endocrinol Metab. 2002;87(2):489-499. doi:10.1210/jcem.87.2.8182 ↩
3. Tomer Y, Ban Y, Concepcion E, et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening. Am J Hum Genet. 2003;73(4):736-747. doi:10.1086/378588 ↩
4. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-2655. doi:10.1056/NEJMra021194 ↩
5. Ott J, Promberger R, Kober F, et al. Hashimoto’s thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid. 2011;21(2):161-167. doi:10.1089/thy.2010.0191 ↩
6. Toulis KA, Anastasilakis AD, Tzellos TG, et al. Selenium supplementation in the treatment of Hashimoto’s thyroiditis: a systematic review and a meta-analysis. Thyroid. 2010;20(10):1163-1173. doi:10.1089/thy.2009.0351 ↩
7. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623-1629. doi:10.1210/jc.2008-1301 ↩
8. Wiersinga WM, Duntas L, Fadeyev V, et al. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. doi:10.1159/000339444 ↩
9. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020 ↩
10. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252-265. doi:10.1007/s12020-012-9703-2 ↩
11. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562. doi:10.1016/S0140-6736(17)30703-1 ↩
12. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43(1):55-68. doi:10.1111/j.1365-2265.1995.tb01894.x ↩
13. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028 ↩